ADVERTISEMENT

Platform Technologies

Genentech Finds Another Nanoparticle Partner In COUR

Deal Snapshot: Genentech will pay $40m up front and in the near term, with milestone fees of up to $900m-plus, to use COUR’s tolerogenic nanoparticle treatments in an undisclosed autoimmune disease.

Novo Nordisk Taps Ascendis For Development Of A Once-Monthly GLP-1 Agonist

Deal Snapshot: Novo is partnering with Ascendis on less frequently dosed drugs for metabolic diseases, committing up to $285m for a lead program, a once-monthly GLP-1 receptor agonist.

Boehringer Sees A Winner In Circle Pharma’s First-In-Class Cancer Approach

Deal Snapshot: Boehringer Ingelheim will work to develop a cyclin inhibitor that can stop cancer cell growth, using Circle’s macrocycle platform.

Research Finds AI Stethoscopes Detect Heart Failure Signs

The results from a trio of studies show that AI-powered digital stethoscopes are effective at identifying patients at elevated risk of experiencing heart attacks and other major cardiac adverse events, according to Eko Health, whose technology was used to screen the participants in the studies.

Generate Snares Novartis As Partner/Investor For Its AI/ML Approach

Like a previous alliance with Amgen, Generate will use its technology to discover and develop computationally designed therapeutic proteins against multiple undisclosed targets.

Israel Startup Licenses Stanford Institute Metabolites To Develop Weight Loss Supplements

Israeli startup by biomedical researcher and entrepreneur Morris Laster using research from ChEM-H Institute scholar at Stanford to will develop and market compounds as nutraceuticals to offer an effective, affordable and side-effect-free solution for weight loss.

FDA Drops Draft Guidance on Predetermined Change Control Plans for Medical Devices

The US FDA has published draft guidance for predetermined change control plans for medical devices along with recommendations for sponsors including them in marketing submissions to the agency.

Empress Looks To The Body’s Internal Chemistry For Drug Leads

Emerging Company Profile: Backed by Flagship Pioneering, Empress deploys its Chemilogics platform to seek leads for small molecule therapies in inflammation, immunology, cancer and metabolic disease.

Halda Raises $126m For First Clinical Trial Of Its RIPTAC Modality

Halda will take its first RIPTAC molecule into a clinical trial in prostate cancer, offering a new small molecule modality in an indication where patients and doctors prefer oral drugs.

Otsuka Gets Discovery Platform, PKU Asset In $1.3bn Jnana Acquisition

Major Japanese firm picks up US drug discovery platform company Jnana in apparent bid to strengthen discovery capabilities and build its mid-stage R&D presence in the renal area.